Ranbaxy, Daiichi to integrate their business operations in Thailand

16 Jan 2013 Evaluate

Ranbaxy Laboratories (Ranbaxy) and Daiichi Sankyo Company (Daiichi) have decided to integrate their business operations in Thailand, to leverage and maximize the synergies of the Hybrid Business Model, which is expected to commence business on April 01, 2018. 

The planned integration or operations will provide a strong foundation for future Daiichi business expansion in Thailand. The development will be mutually beneficial to Ranbaxy and Daiichi and is expected to enhance their competitiveness while offering both innovative and affordable, high quality generic medicines to the people of Thailand as well as generate cost synergies for both companies.

Under this strategy, Daiichi and Ranbaxy would integrate the management of Daiichi’s subsidiary in Thailand, Daiichi Sankyo (Thailand) (DSTH) and Ranbaxy’s Thailand subsidiary, Ranbaxy Unichem Company (RUCL). The new representative of the proposed integrated entity will be Suthas Thongprasert, who presently heads DSTH.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×